Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Expression, Epigenetic and Genetic Changes of HNF1B in Endometrial Lesions

K. Němejcová, I. Tichá, P. Kleiblová, M. Bártů, D. Cibula, K. Jirsová, P. Dundr,

. 2016 ; 22 (3) : 523-530. [pub] 20151219

Language English Country Netherlands

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc17014190

Grant support
NT14001 MZ0 CEP Register

Hepatocyte nuclear factor 1-beta (HNF-1-beta) is a transcription factor involved in cancerogenesis of various tumors, including endometrioid carcinoma. We performed comprehensive analysis of HNF-1-beta in lesions of the endometrium, including protein expression and genetic and epigenetic changes. Expression of HNF-1-beta was analyzed immunohistochemically in 320 cases including both tumor and non-tumor endometrial lesions. Promoter methylation and genetic variants were evaluated, using bisulphite and direct sequencing, in 30 (18 fresh frozen, 12 FFPE tumors) endometrioid carcinomas (ECs) and 15 ovarian clear cell carcinomas (OCCCs) as a control group. We detected expression of HNF-1-beta in 28 % of ECs (51/180 cases), 26 % of serous carcinoma (7/27 cases), 83 % of endometrial clear cell carcinoma (15/18 cases), 93 % of hyperplastic polyps with atypias (13/14 cases), 100 % of hyperplastic polyps without atypias (16/16 cases), 88 % of hyperplasias with atypias (14/16 cases), 91 % of hyperplasias without atypias (10/11 cases), and in ≥80 % of different normal endometrium samples. The control group of OCCCs showed HNF-1-beta expression in 95 % (18/19 cases). Methylation in promoter region was detected in 13.3 % (4/30) of ECs, but not in corresponding normal tissue where available, nor in OCCCs (0/15 cases). Mutation analysis revealed truncating variant c.454C > T (p.Gln152X) in one EC and missense variant c.848C > T (p.Ala283Val) was detected in one OCCC. In conclusion, expression of HNF-1-beta was detected in various extents in all types of lesions analyzed, nevertheless its strong expression was mostly limited to clear cell carcinomas. Biological significance of genetic and epigenetic changes needs further investigation.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17014190
003      
CZ-PrNML
005      
20181112085821.0
007      
ta
008      
170413s2016 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12253-015-0037-2 $2 doi
035    __
$a (PubMed)26685938
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Němejcová, Kristýna $u Department of Pathology, First Faculty of Medicine and General University Hospital, Charles University in Prague, Studnickova 2, 2 12800, Prague, Czech Republic. $7 xx0233214
245    10
$a Expression, Epigenetic and Genetic Changes of HNF1B in Endometrial Lesions / $c K. Němejcová, I. Tichá, P. Kleiblová, M. Bártů, D. Cibula, K. Jirsová, P. Dundr,
520    9_
$a Hepatocyte nuclear factor 1-beta (HNF-1-beta) is a transcription factor involved in cancerogenesis of various tumors, including endometrioid carcinoma. We performed comprehensive analysis of HNF-1-beta in lesions of the endometrium, including protein expression and genetic and epigenetic changes. Expression of HNF-1-beta was analyzed immunohistochemically in 320 cases including both tumor and non-tumor endometrial lesions. Promoter methylation and genetic variants were evaluated, using bisulphite and direct sequencing, in 30 (18 fresh frozen, 12 FFPE tumors) endometrioid carcinomas (ECs) and 15 ovarian clear cell carcinomas (OCCCs) as a control group. We detected expression of HNF-1-beta in 28 % of ECs (51/180 cases), 26 % of serous carcinoma (7/27 cases), 83 % of endometrial clear cell carcinoma (15/18 cases), 93 % of hyperplastic polyps with atypias (13/14 cases), 100 % of hyperplastic polyps without atypias (16/16 cases), 88 % of hyperplasias with atypias (14/16 cases), 91 % of hyperplasias without atypias (10/11 cases), and in ≥80 % of different normal endometrium samples. The control group of OCCCs showed HNF-1-beta expression in 95 % (18/19 cases). Methylation in promoter region was detected in 13.3 % (4/30) of ECs, but not in corresponding normal tissue where available, nor in OCCCs (0/15 cases). Mutation analysis revealed truncating variant c.454C > T (p.Gln152X) in one EC and missense variant c.848C > T (p.Ala283Val) was detected in one OCCC. In conclusion, expression of HNF-1-beta was detected in various extents in all types of lesions analyzed, nevertheless its strong expression was mostly limited to clear cell carcinomas. Biological significance of genetic and epigenetic changes needs further investigation.
650    _2
$a adenokarcinom z jasných buněk $x genetika $x patologie $7 D018262
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a endometroidní karcinom $x genetika $x patologie $7 D018269
650    _2
$a serózní cystadenokarcinom $x genetika $x patologie $7 D018284
650    _2
$a metylace DNA $x genetika $7 D019175
650    _2
$a nádory endometria $x genetika $x patologie $7 D016889
650    _2
$a epigeneze genetická $x genetika $7 D044127
650    _2
$a epigenomika $x metody $7 D057890
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genetická variace $x genetika $7 D014644
650    _2
$a hepatocytární jaderný faktor 1-beta $x genetika $7 D051539
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $x metody $7 D007150
650    _2
$a promotorové oblasti (genetika) $x genetika $7 D011401
655    _2
$a časopisecké články $7 D016428
700    1_
$a Tichá, Ivana $u Department of Pathology, First Faculty of Medicine and General University Hospital, Charles University in Prague, Studnickova 2, 2 12800, Prague, Czech Republic.
700    1_
$a Kleiblová, Petra $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, General University Hospital, Charles University in Prague, Prague, Czech Republic. Institute of Biology and Medical Genetics, First Faculty of Medicine, General University Hospital in Prague, Charles University in Prague, Prague, Czech Republic. $7 xx0125463
700    1_
$a Bártů, Michaela $u First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. $7 xx0233216
700    1_
$a Cibula, David, $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine and General University Hospital, Charles University in Prague, Studnickova 2, 2 12800, Prague, Czech Republic. $d 1968- $7 jo20000074072
700    1_
$a Jirsová, Kateřina, $u Bank of Biological Material, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. $d 1966- $7 xx0101780
700    1_
$a Dundr, Pavel, $u Department of Pathology, First Faculty of Medicine and General University Hospital, Charles University in Prague, Studnickova 2, 2 12800, Prague, Czech Republic. pdundr@seznam.cz. $d 1971- $7 xx0080436
773    0_
$w MED00180530 $t Pathology oncology research POR $x 1532-2807 $g Roč. 22, č. 3 (2016), s. 523-530
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26685938 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20181112085905 $b ABA008
999    __
$a ok $b bmc $g 1200655 $s 974968
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 22 $c 3 $d 523-530 $e 20151219 $i 1532-2807 $m Pathology oncology research $n Pathol Oncol Res $x MED00180530
GRA    __
$a NT14001 $p MZ0
LZP    __
$a Pubmed-20170413

Find record

Citation metrics

Archiving options